GASP-1 Peptide Biomarker Detection via Albumin Complex Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker technologies struggle to detect early stage cancer due to low concentration and rapid turnover of cancer-associated peptides in blood plasma, and existing separation methods fail to distinguish serum albumin complexes, limiting the identification of effective biomarkers for early cancer detection and treatment.
Innovation Solution
The use of G-protein coupled receptor-associated sorting protein 1 (GASP-1) and its peptide fragments as biomarkers, detected through advanced electrophoresis techniques like 2-D High Performance Liquid Electrophoresis (2-D HPLE) and Competitive ELISA, allows for the identification of early stage cancer by analyzing albumin complexes and peptide motifs in blood samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarker detection methods are used, then the detection process is simple, but the sensitivity is insufficient to detect low concentration cancer peptides
Solution Approach 1:
The patent applies segmentation by separating serum albumin complexes from other blood components through advanced electrophoresis techniques. This segmentation isolates the target cancer-associated peptides bound to albumin, enabling sensitive detection despite their low concentration in whole blood plasma.
Solution Approach 2:
The patent uses serum albumin as an intermediary mediator. Cancer-associated peptides that are rapidly cleared from circulation bind to serum albumin, forming stable complexes. This intermediary relationship protects the peptides from degradation and extends their half-life, making them detectable by electrophoresis and Competitive ELISA methods.
2Measurement precision
If advanced electrophoresis techniques like 2-D HPLE are used, then detection sensitivity improves, but the device complexity and operational difficulty increase
Solution Approach 1:
The patent applies preliminary action by performing electrophoretic separation of serum albumin complexes before detection. This preliminary separation step concentrates the cancer-associated peptides in specific bands on the gel, making subsequent detection by Competitive ELISA more efficient and sensitive, while reducing the complexity of the overall process compared to direct detection methods.
3Duration of action of stationary object
If peptide fragments are used as biomarkers, then the biomarker half-life increases, but the concentration in blood plasma remains low
Solution Approach 1:
The patent uses serum albumin as an intermediary that binds to peptide fragments, forming stable complexes. This binding increases the half-life of the peptide fragments from approximately two hours to several days, as the albumin-peptide complexes are protected from renal clearance and proteolytic degradation, enabling detection despite low concentrations.
4Device complexity
If existing separation methods are used, then the process is simple, but the ability to distinguish serum albumin complexes is limited
Solution Approach 1:
The patent applies another dimension by using two-dimensional electrophoresis (2-D HPLE) instead of conventional one-dimensional separation methods. This additional dimension of separation based on isoelectric point and molecular weight enables resolution and differentiation of various serum albumin complexes containing different cancer-associated peptides, providing superior separation precision while maintaining operational feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection of early stage cancer with high sensitivity, allowing for early intervention and treatment before symptoms appear, and provides a method for monitoring cancer progression and therapeutic targeting.
Implementation Method 1
advanced electrophoresis techniques like 2-D High Performance Liquid Electrophoresis (2-D HPLE)
Implementation Method 2
Competitive ELISA, allows for the identification of early stage cancer by analyzing albumin complexes and peptide motifs in blood samples
Data Source
AI summary
A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.